Orforglipron (brand name Foundayo) is a once-daily GLP-1 tablet, and in its clinical trials the most commonly reported side effects were gastrointestinal — chiefly nausea, diarrhoea, constipation and vomiting — which tend to be mild to moderate and most likely during dose increases. These are the same broad class of effects seen with other GLP-1 medicines, because orforglipron works on the same appetite-regulating hormone pathway.
This article explains what the evidence shows, why these effects happen, and how they are usually managed. It is educational information only; orforglipron is a prescription-only medicine and any treatment decision belongs with a GPhC-registered prescriber.
A note on availability first
Orforglipron received a UK marketing authorisation from the MHRA on 10 August 2026 for weight management and type 2 diabetes. Importantly, an authorisation permits a medicine to be prescribed in the UK — it does not mean every pharmacy stocks it.
At The Weight Clinic we do not supply orforglipron yet, but we intend to offer it once we are able to obtain it. In the meantime, our clinicians can discuss the licensed treatments we do provide via a free online consultation. You can read the factual product reference on our Foundayo page.
Why orforglipron causes side effects at all
Orforglipron is a small-molecule (non-peptide) GLP-1 receptor agonist. It mimics a natural gut hormone that signals fullness, slows how quickly the stomach empties, and reduces appetite.
That slowing of the stomach is exactly why gastrointestinal effects are the most common complaint. When food moves through more slowly and appetite drops, the digestive system needs time to adjust — which is why symptoms are usually strongest soon after starting or after a dose increase, then tend to settle.
What the orforglipron trials reported
In the Phase 3 ATTAIN-1 trial, participants on the 36mg dose lost on average 12.4% of their body weight over 72 weeks, alongside lifestyle counselling. Individual results vary; not everyone reaches this.
Across the GLP-1 class, the pattern of reported side effects is consistent. Based on the mechanism and the class as a whole, the most frequently reported effects were gastrointestinal:
- Nausea — often the first symptom, usually mild and temporary.
- Diarrhoea
- Constipation
- Vomiting
- Reduced appetite — an expected effect of how the medicine works, rather than an unwanted one.
Most of these were described as mild to moderate and were most likely during the titration period, when the dose is gradually stepped up. Reporting a side effect does not mean everyone experiences it, and severity differs from person to person.
How orforglipron compares with other GLP-1 medicines on side effects
Because they act on the same pathway, orforglipron shares its side-effect character with other GLP-1 treatments — including the Wegovy injection (semaglutide), the Wegovy Tablet (oral semaglutide), and the dual-hormone medicine Mounjaro (tirzepatide), which acts on GLP-1 and GIP.
The figures quoted here come from different trials with different designs and populations, so they are not head-to-head comparisons. The safe takeaway is that gastrointestinal symptoms are the shared theme across the class, and that a slow, stepwise dose increase is the standard way to reduce them.
| Medicine | Form | Most common side effects |
|---|---|---|
| Orforglipron (Foundayo) | Once-daily tablet | Nausea, diarrhoea, constipation, vomiting, reduced appetite |
| Wegovy (semaglutide) | Weekly injection | GLP-1 class profile — as above |
| Wegovy Tablet (semaglutide) | Daily tablet | GLP-1 class profile — as above |
| Mounjaro (tirzepatide) | Weekly injection | Nausea, diarrhoea, constipation, vomiting, decreased appetite, fatigue |
Serious but rare risks to be aware of
As with GLP-1 medicines generally, rarer but more serious problems are possible and warrant urgent attention. These can include:
- Severe allergic reaction
- Acute pancreatitis (typically severe, persistent stomach pain that may spread to the back)
- Severe or persistent gastrointestinal illness leading to dehydration
- In people with diabetes, severe hypoglycaemia (low blood sugar), particularly if combined with other glucose-lowering medicines
If you experience severe or unrelenting symptoms, signs of an allergic reaction, or intense abdominal pain, seek urgent medical help.
Practical ways to reduce side effects
Many people find gastrointestinal symptoms ease as the body adjusts. Steps that commonly help include:
- Following the prescribed step-up schedule rather than rushing to a higher dose.
- Eating smaller, less fatty meals and stopping when comfortably full.
- Staying well hydrated, especially if you have diarrhoea or vomiting.
- Increasing fibre and fluids gently if constipation is the issue.
- Telling your prescriber if symptoms are persistent or affecting daily life — the plan can be adjusted.
One practical difference worth noting: orforglipron is designed to be taken at any time of day, with or without food or water. That sets it apart from oral semaglutide (the Wegovy Tablet), which must be taken on an empty stomach with a small sip of water, then followed by a 30-minute wait before eating or drinking.
Who these medicines are not suitable for
GLP-1 weight-management treatments are generally not suitable if you are pregnant, planning pregnancy or breastfeeding, have type 1 diabetes, a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastrointestinal disease, an active eating disorder, severe liver or kidney impairment, or a known allergy to the active ingredient. Suitability is assessed on an individual basis at consultation.
Explore the licensed options we currently offer on our treatments overview and weight-loss injections pages, or start a free eligibility check via our online consultation.
Reporting side effects
If you take any medicine and experience a side effect, you can report it directly to the UK regulator through the Yellow Card scheme at https://yellowcard.mhra.gov.uk/. Reporting helps the MHRA monitor the safety of medicines in real-world use.
This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.
